ClinicalTrials.gg
TerminatedNCT03426345Updated Aug 6, 2021Results posted

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

A Phase 3 interventional study of Placebo and Relamorelin in Gastroparesis and Diabetes Mellitus, sponsored by Allergan. Terminated at 240 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-06.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The Relamorelin program is being terminated solely based on a business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Enrollment
11th of 136
311 · median 36
Started
2018
with 11 others
Phase 3
12 of 184
none open now
Registered
91st of 184
by date
Lead sponsor
6 of 184
Allergan

Among the 184 studies in Gastroparesis with a site in United States, this one is the 11th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2018, is one of 12 in phase 3, and was the 91st registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.

03

Conditions studied

  • Gastroparesis
  • Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Type 1 or Type 2 diabetes mellitus
  • Meet the per protocol criteria of diabetic gastroparesis
  • Compliance with diary
  • Compliance with the per protocol study treatment dosing instructions

Exclusion criteria

Exclusion Criteria:

  • Currently receiving nutrition intravenously, by nasogastric tube, or other feeding tube
  • Actively experiencing anorexia nervosa, binge-eating, bulimia or other eating disorder at the time of Screening (Visit 1)
  • Diagnosis of Celiac Disease, also a history of non-celiac gluten sensitivity
  • History of gastrointestinal disorders that may be similar to gastroparesis
  • Functional dyspepsia diagnosed before the diagnosis of diabetes mellitus
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
311 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.

    Drug: Placebo

  • Experimental
    Relamorelin 10 μg

    Following a 2-week placebo run-in, participants received relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 12 weeks.

    Drug: Relamorelin

Interventions

  • DrugPlacebo

    Placebo injected subcutaneously twice daily.

  • Relamorelin 10 μg injected twice daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)

    Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0= no or not at all uncomfortable to 10= worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period.

    Time frame: Baseline (Day-14 to Day-1) to Week 12

  2. Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

    The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during each of the last 6 weeks of the 12-week Treatment Period.

    Time frame: Week 6 to Week 12

Secondary outcomes

  1. Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

    A Nausea Responder was defined as a participant with improvement (decrease) of at least 2-points in the weekly symptom scores for nausea at each of the last 6 weeks of the 12-week Treatment Period. Nausea was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0= no nausea to 10= worst possible nausea.

    Time frame: Baseline (Day-14 to Day-1) to (Week 6 to Week 12)

  2. Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

    An Abdominal Pain Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for abdominal pain at each of the last 6 weeks of the 12-week Treatment Period. Abdominal pain was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0= no abdominal pain to 10= the worst possible abdominal pain and was recorded in an e-diary.

    Time frame: Baseline (Day-14 to Day-1) to (Week 6 to Week 12)

  3. Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

    A Bloating Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for bloating at each of the last 6 weeks of the 12-week Treatment Period. Bloating was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0= no bloating and 10= the worst possible bloating and was recorded in the e-diary.

    Time frame: Baseline (Day-14 to Day-1) to (Week 6 to Week 12)

  4. Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

    A Postprandial Fullness Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for Postprandial Fullness at each of the last 6 weeks of the 12-week Treatment Period. Postprandial Fullness was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0= no feeling of fullness until finishing a meal (best) to 10= feeling full after only a few bites (worst).

    Time frame: Baseline (Day-14 to Day-1) to (Week 6 to Week 12)

  5. Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.

    Time frame: Up to approximately 16 weeks

  6. Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results

    Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

    Time frame: Up to 12 weeks

  7. Number of Participants With Clinically Meaningful Trends for Vital Signs

    Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.

    Time frame: Up to 12 weeks

  8. Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results

    A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.

    Time frame: Up to 12 weeks

  9. Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)

    Time frame: Baseline (Day 1) up to 12 weeks

  10. Number of Participants With Anti-relamorelin Antibody Testing Results by Visit

    A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.

    Time frame: Baseline (Day 1), Day 14, Day 28, Day 84, and End of Treatment (Up to Day 84)

07

Results

Posted Aug 6, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboRelamorelin 10 μg
Started155156
Safety population152155
Completed137139
Not completed1817
Withdrew: Adverse event44
Withdrew: Lack of efficacy10
Withdrew: Withdrawal by subject56
Withdrew: Lost to follow-up31
Withdrew: Protocol deviation34
Withdrew: Reason not specified12
Withdrew: Missing completion status10

Outcome measures

PrimaryChange From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)

Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0= no or not at all uncomfortable to 10= worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period.

Time frame:
Baseline (Day-14 to Day-1) to Week 12
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS)
score on a scalePlaceboRelamorelin 10 μg
Baseline23.4 ± 5.4024.9 ± 6.15
Change from Baseline to Week 12-9.3 ± 10.21-10.2 ± 9.24
PrimaryPercentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during each of the last 6 weeks of the 12-week Treatment Period.

Time frame:
Week 6 to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
percentage of participantsPlaceboRelamorelin 10 μg
Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period19.118.7
SecondaryPercentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

A Nausea Responder was defined as a participant with improvement (decrease) of at least 2-points in the weekly symptom scores for nausea at each of the last 6 weeks of the 12-week Treatment Period. Nausea was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0= no nausea to 10= worst possible nausea.

Time frame:
Baseline (Day-14 to Day-1) to (Week 6 to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
percentage of participantsPlaceboRelamorelin 10 μg
Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period32.938.1
SecondaryPercentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

An Abdominal Pain Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for abdominal pain at each of the last 6 weeks of the 12-week Treatment Period. Abdominal pain was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0= no abdominal pain to 10= the worst possible abdominal pain and was recorded in an e-diary.

Time frame:
Baseline (Day-14 to Day-1) to (Week 6 to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
percentage of participantsPlaceboRelamorelin 10 μg
Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period27.036.1
SecondaryPercentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

A Bloating Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for bloating at each of the last 6 weeks of the 12-week Treatment Period. Bloating was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0= no bloating and 10= the worst possible bloating and was recorded in the e-diary.

Time frame:
Baseline (Day-14 to Day-1) to (Week 6 to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
percentage of participantsPlaceboRelamorelin 10 μg
Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period27.031.6
SecondaryPercentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period

A Postprandial Fullness Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for Postprandial Fullness at each of the last 6 weeks of the 12-week Treatment Period. Postprandial Fullness was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0= no feeling of fullness until finishing a meal (best) to 10= feeling full after only a few bites (worst).

Time frame:
Baseline (Day-14 to Day-1) to (Week 6 to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period
percentage of participantsPlaceboRelamorelin 10 μg
Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period23.727.7
SecondaryNumber of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.

Time frame:
Up to approximately 16 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)
ParticipantsPlaceboRelamorelin 10 μg
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)7586
SecondaryNumber of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results

Clinical Laboratory tests included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
ParticipantsPlaceboRelamorelin 10 μg
Eosinophils Absolute Cell Count [10^9/liter (L)]: >3×Upper Limit of Normal Value (ULN)01
Hematocrit (RATIO): >1.1×ULN10
Hematocrit (RATIO): <0.9×Lower Limit of Normal Value (LLN)44
Hemoglobin [grams (g)/L]: <0.9×LLN25
Lymphocytes Absolute Cell Count (10^9/L): <0.8×LLN13
Mean Corpuscular Volume [femtoliter(fL)]: >1.1×ULN11
Neutrophils Absolute Cell Count (10^9/L): >1.5×ULN01
Neutrophils Absolute Cell Count (10^9/L): <0.8×LLN22
Red Blood Cell Count (10^12/L): <0.9×LLN11
Alanine Aminotransferase [Serum Glutamic Pyruvic Transaminase (SGPT)] [unit(U)/L]: >=3×ULN10
Albumin (g/L): <0.9×LLN01
Alkaline Phosphatase (U/L): >=3×ULN10
Aspartate Aminotransferase [Serum Glutamic Oxaloacetic Transaminase (SGOT)] (U/L): >=3×ULN12
Bicarbonate (HCO3) [millimoles (mmol)/L]: >1.1×ULN01
Bicarbonate (HCO3) (mmol/L): <0.9×LLN10
Blood Urea Nitrogen (mmol/L): >1.2×ULN153
Chloride (mmol/L): <0.9×LLN20
Cholesterol, Total, Fasting (mmol/L): >1.6×ULN21
Creatinine [micromoles(μmol)/L]: >1.3×ULN87
Glucose-Chemistry, Fasting (mmol/L): >2.5×ULN1121
Glucose-Chemistry, Fasting (mmol/L): <0.9×LLN65
Glycohemoglobin A1C: Increase of >=0.5%80111
Glycohemoglobin A1C: Increase of >=1%80111
Phosphorus (mmol/L): >1.1×ULN55
Phosphorus (mmol/L): <0.9×LLN11
Potassium (mmol/L): <0.9×LLN10
Sodium (mmol/L): <0.9×LLN10
Triglycerides, Fasting (mmol/L): >=3×ULN35
Uric Acid (Urate) (μmol/L): >1.1×ULN1813
Uric Acid (Urate) (μmol/L): <0.9×LLN30
SecondaryNumber of Participants With Clinically Meaningful Trends for Vital Signs

Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the abnormal results were clinically significant.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Trends for Vital Signs
ParticipantsPlaceboRelamorelin 10 μg
Number of Participants With Clinically Meaningful Trends for Vital Signs00
SecondaryNumber of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results

A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results
ParticipantsPlaceboRelamorelin 10 μg
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results12
SecondaryNumber of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)
Time frame:
Baseline (Day 1) up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)
ParticipantsPlaceboRelamorelin 10 μg
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)80111
SecondaryNumber of Participants With Anti-relamorelin Antibody Testing Results by Visit

A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay. The number of participants in each of the following categories are reported: Negative Screening Test, Positive Screening Test, Negative Confirmatory Test, and Positive Confirmatory Test at each time point.

Time frame:
Baseline (Day 1), Day 14, Day 28, Day 84, and End of Treatment (Up to Day 84)
Reported as:
Count of participants · Participants
Number of Participants With Anti-relamorelin Antibody Testing Results by Visit
ParticipantsRelamorelin 10 μg
Screening Test (Baseline) — Negative127
Screening Test (Baseline) — Positive18
Confirmatory Test (Baseline) — Negative12
Confirmatory Test (Baseline) — Positive0
Screening Test (Day 14) — Negative115
Screening Test (Day 14) — Positive18
Confirmatory Test (Day 14) — Negative13
Confirmatory Test (Day 14) — Positive0
Screening Test (Day 28) — Negative104
Screening Test (Day 28) — Positive17
Confirmatory Test (Day 28) — Negative12
Confirmatory Test (Day 28) — Positive0
Screening Test (Day 84) — Negative87
Screening Test (Day 84) — Positive17
Confirmatory Test (Day 84) — Negative11
Confirmatory Test (Day 84) — Positive1
Screening Test (End of Treatment) — Negative6
Screening Test (End of Treatment) — Positive1
Confirmatory Test (End of Treatment) — Negative1
Confirmatory Test (End of Treatment) — Positive0
Screening Test (Unscheduled) — Negative6
Screening Test (Unscheduled) — Positive0
Positive Confirmatory Test (Unscheduled) — Negative—
Positive Confirmatory Test (Unscheduled) — Positive—

Adverse events

Collected over Up to approximately 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/155 (0%)6/152 (3.9%)14/152 (9.2%)
Relamorelin 10 μg0/156 (0%)8/155 (5.2%)13/155 (8.4%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPlaceboRelamorelin 10 μg
Vaginal haemorrhageReproductive system and breast disorders0/1091/113
Cardiac failure congestiveCardiac disorders1/1521/155
InfluenzaInfections and infestations1/1520/155
SepsisInfections and infestations1/1520/155
Upper respiratory tract infectionInfections and infestations1/1520/155
DehydrationMetabolism and nutrition disorders1/1521/155
Diabetic ketoacidosisMetabolism and nutrition disorders1/1521/155
MalnutritionMetabolism and nutrition disorders1/1520/155
Muscular weaknessMusculoskeletal and connective tissue disorders1/1520/155
HeadacheNervous system disorders1/1520/155
Most frequent other events
Most frequent other events
EventPlaceboRelamorelin 10 μg
DiarrhoeaGastrointestinal disorders9/1525/155
Urinary tract infectionInfections and infestations5/1529/155

Baseline characteristics

Intent-to-treat (ITT) Population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboRelamorelin 10 μgTotal
Mean54.1 ± 12.1355.8 ± 12.0755.0 ± 12.11
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRelamorelin 10 μgTotal
Female112114226
Male434285
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRelamorelin 10 μgTotal
Hispanic or Latino5451105
Not Hispanic or Latino101105206
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRelamorelin 10 μgTotal
American Indian or Alaska Native4711
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American251742
White123127250
More than one race235
Unknown or Not Reported000
08

Study locations

240 sites
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • Synexus Clinical Research US - Simon Williamson Clinic
    Birmingham, Alabama 35211, United States
  • G & L Research, LLC
    Foley, Alabama 36535, United States
  • Alabama Medical Group, PC
    Mobile, Alabama 36608, United States
  • Synexus Clinical Research US, Inc.
    Tucson, Arizona 85741, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • Unity Health - Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • GW Research Inc.
    Chula Vista, California 91910, United States
  • Diagnamics Inc.
    Encinitas, California 92024, United States
  • Fresno Clinical Research Center
    Fresno, California 93720, United States
  • Torrance Clinical Research Institute, Inc.
    Lomita, California 90717, United States
  • Tibor Rubin VA Medical Center
    Long Beach, California 90822, United States
  • Angel City Research Inc.
    Los Angeles, California 90026, United States
  • Facey Medical Foundation
    Mission Hills, California 91345, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • Stanford Hospital, Digestive Health Clinic
    Palo Alto, California 94304, United States
  • TriWest Research Associates
    Poway, California 92064, United States
  • Optimal Research California
    San Diego, California 92108, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • New Hope Research Development
    Whittier, California 90603, United States
  • Synexus Clinical Research US, Inc. - Colorado Springs Family Practice
    Colorado Springs, Colorado 80909, United States
  • Gastroenterology Associates of Fairfield County, P.C.
    Bridgeport, Connecticut 06824, United States
  • Visionary Investigators Network
    Aventura, Florida 33180, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • ALL Medical Research LLC
    Cooper City, Florida 33024, United States
  • Palmetto Research, LLC
    Hialeah, Florida 33016, United States
  • Vida Clinical Trials
    Homestead, Florida 33030, United States
  • Sanchez Clinical Research, Inc.
    Miami, Florida 33157, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Synexus
    Pinellas Park, Florida 33781, United States
  • Cleveland Clinic Florida - Weston
    Weston, Florida 33331, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • River Birch Research Alliance, LLC
    Blue Ridge, Georgia 30513, United States
  • Gwinnett Research Institute, LLC
    Buford, Georgia 30519, United States
  • iResearch Atlanta LLC
    Decatur, Georgia 30030, United States
  • Clinical Research Consultants of Atlanta
    Suwanee, Georgia 30024, United States
  • Rocky Mountain Diabetes and Osteoporosis Center, PA
    Idaho Falls, Idaho 83404-7596, United States
  • Synexus Clinical Research US, Inc.
    Chicago, Illinois 60602, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • North Shore University Health System
    Evanston, Illinois 60201, United States
  • American Research, LLC
    Jeffersonville, Indiana 47130, United States
  • Gastroenterology of Southern Indiana
    New Albany, Indiana 47150, United States
  • Health Science Research Center
    Pratt, Kansas 67124, United States
  • WestGlen Gastrointestinal Consultants
    Shawnee Mission, Kansas 67214, United States
  • Kansas Medical Clinic
    Topeka, Kansas 66606, United States
  • Professional Research Network of Kansas, LLC
    Wichita, Kansas 67205, United States
  • Via Christi Clinic, PA
    Wichita, Kansas 67208, United States
  • Tri-State Gastroenterology
    Crestview Hills, Kentucky 41017, United States
  • WK Physicians Network
    Bossier City, Louisiana 71111, United States
  • Avant Research Associates LLC
    Crowley, Louisiana 70526, United States
  • Clinical Trials of SWLA, LLC
    Lake Charles, Louisiana 70601, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Clinical Trials of America, Inc.
    West Monroe, Louisiana 71291, United States
  • Trialspark - Sood
    Bowie, Maryland 20716, United States
  • Capital Diabetes and Endocrine Associates
    Camp Springs, Maryland 20746, United States
  • Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Woodholme Gastroenterology Associates, P.A.
    Glen Burnie, Maryland 21061, United States
  • Meritus Center for Clinical Research
    Hagerstown, Maryland 21742, United States
  • Meridian Clinical Research, LLC
    Rockville, Maryland 20854, United States
  • Commonwealth Clinical Studies, PLLC.
    Brockton, Massachusetts 02302, United States
  • Clinical Research Institute of Michigan
    Chesterfield, Michigan 48047, United States
  • Aa Mrc Llc
    Flint, Michigan 48504, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
  • Synexus Clinical Research US, Inc
    Saint Louis, Missouri 63141, United States
  • Heartland Clinical Research, Inc
    Omaha, Nebraska 68134, United States
  • USMA Clinical Research, LLC
    Elizabeth, New Jersey 07201, United States
  • Lovelace Scientific Resources, Inc.
    Albuquerque, New Mexico 87108, United States
  • Synexus Clinical Research US, Inc.
    Jamaica, New York 11432, United States
  • Winthrop-University Hospital
    Mineola, New York 11501, United States
  • Carolina Digestive Health Associates, PA
    Davidson, North Carolina 28036, United States
  • Kinston Medical Specialists, P.A.
    Kinston, North Carolina 28501, United States
  • Diabetes and Endocrinology Consultants, PC
    Morehead City, North Carolina 28557, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • PMG Research of Winston-Salem, LLC
    Winston-Salem, North Carolina 27103, United States
  • Synexus Clinical Research US, Inc.
    Akron, Ohio 44311, United States
  • Diabetes & Endocrinology Associates of Stark County, Inc.
    Canton, Ohio 44718, United States
  • Synexus Clinical Research US - Cincinnati
    Cincinnati, Ohio 45236, United States
  • Synexus Clinical Research US, Inc
    Cincinnati, Ohio 45249, United States
  • The MetroHealth System MHS
    Cleveland, Ohio 44109-1998, United States
  • Digestive Disease & Surgery Institute
    Cleveland, Ohio 44195, United States
  • The Ohio State University, Wexner Medical Center
    Columbus, Ohio 43203, United States
  • Aventiv Research, Inc.
    Columbus, Ohio 43213, United States
  • CIC America Clinical Inquest Center Ltd.
    Dayton, Ohio 45409, United States
  • Hometown Urgent Care and Research
    Dayton, Ohio 45424, United States
  • Centennial Health-Synexus
    Oklahoma City, Oklahoma 73111, United States
  • Options Health Research, LLC
    Tulsa, Oklahoma 74104, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny Endocrinology Associates
    Pittsburgh, Pennsylvania 15212, United States
  • Guthrie Clinical Research
    Sayre, Pennsylvania 18840, United States
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Care Access Research
    Warwick, Rhode Island 02886, United States
  • Synexus Clinical Research US, Inc.
    Anderson, South Carolina 29621, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Clinsearch
    Chattanooga, Tennessee 37421, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • East Tennessee Research Institute
    Johnson City, Tennessee 37604, United States
  • Texas Clinical Research Institute, LLC
    Arlington, Texas 76012, United States

Showing the first 100 of 240 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jul 2020, 29 months.

Results were first posted in Aug 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2018
First posted
Feb 8, 2018
StartActual
Feb 16, 2018
Primary completionActual
Jul 16, 2020
CompletionActual
Jul 16, 2020
Results first posted
Aug 6, 2021
Last update
Aug 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03426345
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Feb 8, 2018
Start date
Feb 16, 2018
Primary completion
Jul 16, 2020
Completion
Jul 16, 2020
Results posted
Aug 6, 2021
Last update
Aug 6, 2021

Study contacts

Wieslaw (Wes) Bochenek, MD, PhD
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relamorelin

Start the discussion